Acquisition of Cytiva NanoAssemblr Ignite & Spark Microfluidic Nanoparticle For
Closed Special Notice Posted
- Solicitation number
- 75N92025Q00151
- Agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Points of contact
- More information
Notice details come from SAM.gov. Updated .
About this opportunity
The National Heart Lung and Blood Institute, part of the National Institutes of Health within the Department of Health and Human Services, has issued a Special Notice for the acquisition of Cytiva NanoAssemblr Ignite & Spark Microfluidic Nanoparticle Formulation Systems. This procurement opportunity focuses on acquiring specialized laboratory equipment for gene therapy development applications. The notice was posted on September 12, 2025, and falls under the Analytical Laboratory Instrument Manufacturing NAICS code 334516 and Laboratory Equipment and Supplies PSC code 6640. The opportunity does not utilize any set-aside designations, making it open to all eligible contractors. This acquisition represents the agency's investment in advanced microfluidic technology for research purposes.
The primary objective of this Special Notice is to procure sophisticated nanoparticle formulation systems that will support gene therapy research and development initiatives at the National Heart Lung and Blood Institute. Interested contractors must respond by the due date of September 17, 2025, providing them with a brief five-day window from the posting date to prepare and submit their responses. The procurement targets companies capable of supplying Cytiva's specific NanoAssemblr technology, which suggests the agency has identified particular technical requirements that these systems fulfill. Since no set-aside restrictions apply, contractors of all sizes and classifications may participate in this opportunity. The acquisition of these microfluidic systems indicates the agency's commitment to advancing gene therapy research capabilities through state-of-the-art laboratory instrumentation. The tight timeline suggests this may be an urgent procurement need related to ongoing or upcoming research projects.
Notice text
Acquisition of Cytiva NanoAssemblr Ignite & Spark Microfluidic Nanoparticle Formulation Systems for Gene Therapy Development
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| NIA:Non-Competitive Combined Synopsis/Solicitation | Office of Logisitics and Acquisition Operations | No set-aside | |
| Hidex 600SLe Liquid Scintillation Counter | National Institute on Drug Abuse | No set-aside | |
| 1-Year OEM Service Contract - (2) Revvity Celigo S Imaging Instruments (VRC) | National Institute of Allergy and Infectious Diseases | No set-aside | |
| TIDAL: Target-Induced Droplet Assembly of Ligands | Department of Energy | No set-aside | |
| Service Maintenance for UM Blaze Microscope System | Office of Logisitics and Acquisition Operations | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity